ArticleInternational journal of nanomedicine2026
Liposomal-Mitoxantrone Overcomes Acquired Resistance and Enhances Venetoclax Synergy in AML-Mechanistic Insights and Preliminary Clinical Evidence.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Liposomal drug delivery has emerged as a promising strategy to improve the efficacy and safety of chemotherapeutic agents, yet whether and how liposomal reformulation fundamentally reshapes therapeutic response and resistance evolution remains unclear. This study compared liposomal mitoxantrone with free mitoxantrone and examined their effects on antileukemic activity, hematologic toxicity, resistance development, and cell-death pathways. Methods: Liposomal and free mitoxantrone were evaluated in an MLL-AF9-driven acute myeloid leukemia mouse model by survival analysis and peripheral blood measurements. Secondary transplantation experiments were performed to evaluate the sensitivity of residual leukemia cells. Single-cell RNA sequencing was used to characterize transcriptional features of residual leukemia cells. Drug combination with venetoclax and the cell killing pattern of the two drugs were explored based on MOLM13 cell line. Exploratory clinical observations were additionally obtained from four patients who received liposomal mitoxantrone in combination with venetoclax. Results: Liposomal mitoxantrone significantly prolonged mouse survival compared with free-mitoxantrone and control groups (both p < 0.001), while causing minimal myelosuppression. In contrast, free-mitoxantrone induced marked hematologic toxicity. Secondary transplantation demonstrated that residual cells following free-mitoxantrone treatment developed resistance upon re-exposure (p < 0.001), while those from liposomal-treated mice retained drug sensitivity and conferred sustained survival benefit (both p < 0.01). Single-cell RNA sequencing revealed that free-mitoxantrone induced transcriptional heterogeneity, characterized by enhanced metabolic and immune-related pathways, and monocyte-like features, whereas liposomal-mitoxantrone preserved a proliferative state similar to untreated cells. Consistently, liposomal-mitoxantrone demonstrated stronger synergistic effects with venetoclax. Discussion: Liposomal reformulation altered the therapeutic, transcriptional, and cell-death pattern of mitoxantrone in the models. These findings suggest that liposomal mitoxantrone may reduce hematologic toxicity and limit the emergence of drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.